• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

In older persons at risk for dementia, a multidomain approach reduced stroke and transient ischemic attack
Ann Intern Med. 2022 May 3. doi: 10.7326/J22-0030. Online ahead of print.ABSTRACTLehtisalo J, Rusanen M, Solomon A, et al. Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial. Eur Heart J. 2022. [Epub ahead of print.] 35051281.PMID:35500268 | DOI:10.7326/J22-0030
Source: Annals of Internal Medicine - May 2, 2022 Category: Internal Medicine Authors: Konstantin A Krychtiuk Christopher B Granger Source Type: research

Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study
CONCLUSION: Beyond excess deaths alone, the COVID-19 pandemic imposed a greater life expectancy burden on persons aged 25 to 64 years, including those with average or above-average life expectancies, and a disproportionate burden on Black and Hispanic communities.PRIMARY FUNDING SOURCE: National Institute on Aging.PMID:34543588 | DOI:10.7326/M21-2239
Source: Annals of Internal Medicine - September 20, 2021 Category: Internal Medicine Authors: Julian Reif Hanke Heun-Johnson Bryan Tysinger Darius Lakdawalla Source Type: research

Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
Conclusion: Evidence does not support use of the studied pharmacologic treatments for cognitive protection in persons with normal cognition or MCI. Primary Funding Source: Agency for Healthcare Research and Quality. PMID: 29255847 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - December 19, 2017 Category: Internal Medicine Authors: Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL Tags: Ann Intern Med Source Type: research

Review: Cholinesterase inhibitors do not reduce progression to dementia from mild cognitive impairment.
CONCLUSION In adults with mild cognitive impairment, cholinesterase inhibitors do not differ from placebo for progression to dementia at 1 and 3 years but increase nonserious adverse events.Cholinesterase inhibitors (ChEIs) vs placebo in adults with mild cognitive impairment*OutcomesNumber of trials (n)Weighted event ratesAt 16 wk to 3 yChEIsPlaceboRRR (95% CI)NNT (CI)Dementia at 1 y3 (2560)7.6%12%31% (0 to 53)NSDementia at 2 y2 (2048)12%18%33% (17 to 45)17 (12 to 34)Dementia at 3 y2 (1530)20%24%16% (-2 to 30)NSSerious adverse events6 (4207)19%19%3% (-10 to 14)NSRRI (CI)NNH (CI)Any adverse event6 (4207)89%82%9% (2 to 16)15...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Masoodi N Tags: Ann Intern Med Source Type: research

The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study.
CONCLUSION: Higher midlife fitness levels seem to be associated with lower hazards of developing all-cause dementia later in life. The magnitude and direction of the association were similar with or without previous stroke, suggesting that higher fitness levels earlier in life may lower risk for dementia later in life, independent of cerebrovascular disease. PRIMARY FUNDING SOURCE: The Cooper Institute; University of Texas Southwestern Medical Center; National Heart, Lung, and Blood Institute; and American Heart Association. PMID: 23381040 [PubMed - in process]
Source: Annals of Internal Medicine - February 5, 2013 Category: Internal Medicine Authors: Defina LF, Willis BL, Radford NB, Gao A, Leonard D, Haskell WL, Weiner MF, Berry JD Tags: Ann Intern Med Source Type: research

Ginkgo biloba extract did not reduce risk for Alzheimer disease in elderly patients with memory complaints.
CONCLUSION Ginkgo biloba extract did not reduce risk for Alzheimer disease in elderly patients who reported memory complaints to their primary care physicians.Ginkgo biloba extract vs placebo for incident Alzheimer disease in elderly patients with memory complaints†YearGinkgo biloba extractPlaceboRRR (95% CI)NNT10.7%1.0%28% (-61 to 68)Not significantRRI (CI)NNH21.7%1.0%65% (-19 to 236)Not significant†Abbreviations defined in Glossary. RRR, RRI, NNT, NNH, and CI calculated from placebo event rates and hazard ratios in article. PMID: 23318341 [PubMed - in process]
Source: Annals of Internal Medicine - January 15, 2013 Category: Internal Medicine Authors: Hirsch C Tags: Ann Intern Med Source Type: research